Clinical Chemistry AACC Online Job Center
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Clinical Chemistry 48: 489-498, 2002;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (19)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Miller, W. G.
Right arrow Articles by Jayne, E. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Miller, W. G.
Right arrow Articles by Jayne, E. C.
Related Collections
Right arrow Lipids, Lipoproteins, and Cardiovascular Risk Factors
(Clinical Chemistry. 2002;48:489-498.)
© 2002 American Association for Clinical Chemistry, Inc.

Performance of Four Homogeneous Direct Methods for LDL-Cholesterol

W. Greg Miller1a, Parvin P. Waymack2, F. Philip Anderson1, Steven F. Ethridge2 and Eduviges C. Jayne1

1 Department of Pathology, Virginia Commonwealth University Health System, Richmond, VA 23298.

2 CDC, National Center for Environmental Health, Division of Laboratory Sciences, Special Activities Branch, Atlanta, GA 30341.

aAddress correspondence to this author at: Virginia Commonwealth University, 401 N. 13th St., Richmond, VA 23219. Fax 804-828-0353; e-mail millerg{at}hsc.vcu.edu.

Background: Homogeneous LDL-cholesterol methods from Genzyme, Reference Diagnostics, Roche, and Sigma were evaluated for precision, accuracy, and specificity for LDL in the presence of abnormal lipoproteins.

Methods: Each homogeneous method was performed by a Roche/Hitachi 911 according to the vendors’ instructions, and the results were compared with the ß-quantification reference method. We measured precision over 20 days using quality-control and frozen serum specimens. Sera from 100 study participants, including 60 with hyperlipidemias, were assayed by each method. Accuracy was evaluated from regression and total error analysis. Specificity was evaluated from the bias (as a percentage) vs concentration of triglycerides.

Results: The total CV was <2% for all methods. Regression slope and intercept (with 95% confidence intervals) were as follows: Genzyme, 0.955 (0.92 to 0.99) and 30.3 (-12 to 73) mg/L; Reference Diagnostics, 0.975 (0.93 to 1.02) and -8 (-63 to 47) mg/L; Roche, 1.067 (1.02 to 1.11) and -101 (-161 to -42) mg/L; and Sigma, 0.964 (0.91 to 1.02) and 164 (89 to 239) mg/L. The percentages of individual results with >12% bias were as follows: Genzyme, 8.0%; Reference Diagnostics, 11.0%; Roche, 10.0%; and Sigma, 30.0%. Total error calculated from mean systematic bias and all-sources random bias was as follows: Genzyme, 12.6%; Reference Diagnostics, 16.5%; Roche, 41.6%; and Sigma, 38.3%. Slopes of bias (as a percentage) vs triglycerides were P <0.001 for all methods except the Roche method, which was P = 0.094.

Conclusions: The evaluated methods show nonspecificity toward abnormal lipoproteins, thus compromising their ability to satisfy the National Cholesterol Education Program goal for a total error of <12%. These homogeneous LDL-cholesterol results do not improve on the performance of LDL-cholesterol calculated by the Friedewald equation at triglyceride concentrations <4000 mg/L.




The following articles in journals at HighWire Press have cited this article:


Home page
CLIN PEDIATRHome page
S. de Ferranti, D. Shapiro, R. Markowitz, E. Neufeld, N. Rifai, and H. Bernstein
Nonfasting Low-Density Lipoprotein Testing: Utility for Cholesterol Screening in Pediatric Primary Care
Clinical Pediatrics, June 1, 2007; 46(5): 441 - 445.
[Abstract] [PDF]


Home page
Clin. Chem.Home page
D. J. Blom, F. H. O'Neill, and A. D. Marais
Screening for Dysbetalipoproteinemia by Plasma Cholesterol and Apolipoprotein B Concentrations
Clin. Chem., May 1, 2005; 51(5): 904 - 907.
[Full Text] [PDF]


Home page
J CARDIOVASC PHARMACOL THERHome page
E. T. Bairaktari, K. I. Seferiadis, and M. S. Elisaf
Evaluation of Methods for the Measurement of Low-Density Lipoprotein Cholesterol
Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 2005; 10(1): 45 - 54.
[Abstract] [PDF]


Home page
Clin. Chem.Home page
J. S. Krouwer
Critique of the Guide to the Expression of Uncertainty in Measurement Method of Estimating and Reporting Uncertainty in Diagnostic Assays
Clin. Chem., November 1, 2003; 49(11): 1818 - 1821.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
S. Usui, H. Kakuuchi, M. Okamoto, Y. Mizukami, and M. Okazaki
Differential Reactivity of Two Homogeneous LDL-Cholesterol Methods to LDL and VLDL Subfractions, as Demonstrated by Ultracentrifugation and HPLC
Clin. Chem., November 1, 2002; 48(11): 1946 - 1954.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
G. R. Warnick, W. G. Miller, P. P. Waymack, and F. P. Anderson
Lack of Agreement of Homogeneous Assays with the Reference Method for LDL-Cholesterol May Not Indicate Unreliable Prediction of Risk for Cardiovascular Disease * Authors of the article cited above respond:
Clin. Chem., October 1, 2002; 48(10): 1812 - 1815.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2002 by the American Association for Clinical Chemistry.